Dosing considerations for rufinamide in patients with Lennox –Gastaut syndrome: Phase III trial results and real-world clinical data

Conclusions A lower dose and slower titration schedule (“low and slow”) may reduce incidence of AEs without compromising efficacy of rufinamide in LGS.

Source: Seizure - March 8, 2017 Category: Neurology Source Type: research